Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

@article{Feldman2011DiscoveryOR,
  title={Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.},
  author={Andrew L. Feldman and Ahmet Dogan and David I. Smith and Mark E. Law and Stephen M. Ansell and Sarah H. Johnson and Julie C. Porcher and Nazan Ozsan and Eric D. Wieben and Bruce W. Eckloff and George Vasmatzis},
  journal={Blood},
  year={2011},
  volume={117 3},
  pages={
          915-9
        }
}
The genetics of peripheral T-cell lymphomas are poorly understood. The most well-characterized abnormalities are translocations involving ALK, occurring in approximately half of anaplastic large cell lymphomas (ALCLs). To gain insight into the genetics of ALCLs lacking ALK translocations, we combined mate-pair DNA library construction, massively parallel ("Next Generation") sequencing, and a novel bioinformatic algorithm. We identified a balanced translocation disrupting the DUSP22 phosphatase… 

Figures and Tables from this paper

Primary Cutaneous CD 30-Positive T-Cell Lymphoproliferative Disorders with Biallelic Rearrangements of DUSP 22
TLDR
Three cases of cutaneous ALCL are presented, classified according to the WHO/EORTC (World Health Organization/European Organization for Research and Treatment of Cancer) classification system, with at least two copies of chromosome 6 bearing a 6p25.3 translocation and no intact copies of the normal 6p 25.3 allele, indicating at least one mechanism for abolishing DUSP22 expression in T-cell lymphomas.
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.
TLDR
It is suggested that a constellation of alternate genetic abnormalities may contribute to disruption of p53-associated tumor suppressor function in PTCL.
Peripheral T-cell lymphoma with t(6;14)(p25;q11.2) translocation presenting with massive splenomegaly
TLDR
This case of PTCL, not otherwise specified, with the karyotype 46,Y,add(X)(p22),t(6;14)(p25;q11) and FISH-proved breakpoints in the IRF4 and TCRAD loci is reported, supporting consideration of this translocation as a marker of biological aggressiveness.
Primary cutaneous CD30-positive T-cell lymphoproliferative disorders with biallelic rearrangements of DUSP22.
TLDR
Three cases of cutaneous ALCL are presented, classified according to the WHO/EORTC (World Health Organization/European Organization for Research and Treatment of Cancer) classification system, with at least two copies of chromosome 6 bearing a 6p25.3 translocation and no intact copies of the normal 6p 25.3 allele, indicating at least one mechanism for abolishing DUSP22 expression in T-cell lymphomas.
Genome-wide analysis reveals recurrent structural abnormalities of TP 63 and other p 53-related genes in peripheral T-cell lymphomas Running head : Genome-wide analysis of T-cell lymphomas
TLDR
It is suggested that a constellation of alternate genetic abnormalities may contribute to disruption of p53-associated tumor suppressor function in PTCL.
Co-occurring rearrangements of DUSP22 and TP63 define a rare genetic subset of ALK-negative anaplastic large cell lymphoma with inferior survival outcomes
TLDR
The case presented here adds to a growing body of evidence demonstrating that rearrangements of DUSP22 and TP63 in ALK-negative ALCL can, on rare occasions, co-occur.
Identification of high‐risk DUSP22‐rearranged ALK‐negative anaplastic large cell lymphoma
TLDR
Evaluated the frequency, clinical features and outcome of previously defined ALCL genetic subgroups in an independent series of systemic ALCL and the prognostic significance of immunohistochemical (IHC) markers was explored.
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma.
TLDR
The data justify the possibility of translating quantitative RT-PCR protocols to routine clinical settings as a new approach to objectively dissect T-NHL and to select more appropriate therapeutic protocols.
JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology
TLDR
The findings suggest that a subset of CD30+ ALK− systemic PTCL with anaplastic morphology carry JAK2 rearrangements, some of which appear to show CHL-like morphologic features.
...
...

References

SHOWING 1-10 OF 29 REFERENCES
Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue.
TLDR
NAV3, a novel putative haploinsufficient tumor suppressor gene, is disrupted in most cases of the commonest types of CTCL and may thus provide a new diagnostic tool.
Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas
TLDR
Recurrent translocations involving the multiple myeloma oncogene-1/interferon regulatory factor-4 (IRF4) locus in PTCLs are identified and MUM1/ IRF4 protein may play an important biologic role in some PTCS, and might represent a possible therapeutic target.
Anaplastic large cell lymphoma, ALK-negative.
Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma.
TLDR
It is concluded that ALCL is a heterogeneous disorder, however, ALK protein expression is an independent predictor of survival and serves as a useful biologic marker of a specific disease entity within the spectrum of ALCL.
t(3;7)(q27;q32) fuses BCL6 to a non-coding region at FRA7H near miR-29
TLDR
Involvement of the dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells and its role in membrane structure, dynamics, signaling and autophagy is studied.
Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy
TLDR
A succinct summary of normal ALK biology, the confirmed and putative roles of ALK fusions and the full‐length ALK receptor in the development of human cancers, and efforts to target ALK using small‐molecule kinase inhibitors is provided.
Analysis of chronic lymphotic leukemia transcriptomic profile: differences between molecular subgroups
TLDR
Functional profiling methods allowed us to distinguish KEGG and gene ontology terms showing coordinated gene expression changes across subgroups of CLL, and validated a set of differentially expressed genes according to IgVH status, scoring them as putative prognostic markers in CLL.
Loss of SHP 1 Enhances JAK 3 / STAT 3 Signaling and Decreases Proteosome Degradation of JAK 3 and NPM-ALK in ALK-positive Anaplastic Large Cell Lymphoma
TLDR
Loss of SHP1 contributes to the pathogenesis of ALK+ALCL by two mechanisms: 1) leaves the tyrosine phosphorylation and activation of JAK3/STAT3 unchecked, and 2) decreases proteosome degradation of Jak3 and NPM-ALK.
Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues.
TLDR
Analysis of data from a large tumor lymphoma data bank including 194 cases of lymphoproliferative disorders of B- and T-cell origin as well as reactive lymphoid tissues indicates that TCL1 is expressed in more differentiated B cells, under both reactive and neoplastic conditions, from antigen committed B cells and in germinal center B cell cells and is down-regulated in the latest stage ofB-cell differentiation.
Transcriptome Sequencing to Detect Gene Fusions in Cancer
TLDR
A robust pipeline is established for the discovery of novel gene chimaeras using high-throughput sequencing of cancer cells to discover novel gene fusions resulting in chimaeric transcripts in cancer cell lines and tumours.
...
...